A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

RC148 Monotherapy

RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle

DRUG

RC148+docetaxel Combination Therapy

RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.

DRUG

RC148+RC48 Combination Therapy

RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle; RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.

DRUG

RC148+RC88 Combination Therapy

RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.

DRUG

RC148/Bevacizumab+RC88 Combination Therapy

RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle

Trial Locations (31)

Unknown

RECRUITING

Anhui Provincial Hospital, Anhui

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

RECRUITING

Beijing University Cancer Hospital, Beijing

RECRUITING

The Fifth Medical Center of Chinese PLA General Hospital, Beijing

RECRUITING

Jilin Cancer Hospital, Changchun

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Hunan Second People's Hospital, Changsha

RECRUITING

Sichuan Cancer Hospital, Chengdu

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The Second Affiliated Hospital of Guilin Medical University, Guilin

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Qilu Hospital of shangdong university, Jinan

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Meizhou People's Hospital, Meizhou

RECRUITING

Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute, Nanning

RECRUITING

Nanyang City Center Hospital, Nanyang

RECRUITING

Nanyang Second General Hospital, Nanyang

RECRUITING

Shanghai Pulmonology Hospital, Shanghai

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

RECRUITING

Shanxi Provincial Tumor Hospital, Taiyuan

RECRUITING

Tongji Hospital, Tongji Medical College of HUST, China, Wuhan

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, Wuhan

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Yunnan Cancer Hospital, Yunnan

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT06016062 - A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | Biotech Hunter | Biotech Hunter